Insulet Corporation (PODD) Receives Price Target

Insulet Corporation (PODD) : 11 investment research analysts covering Insulet Corporation (PODD) have an average price target of $43.02 for the near short term. The highest target price given by the Brokerage Firm to the stock is $52 and the lowest target is $39 for the short term. Analysts expect the variance to be within $4.86 of the average price.

Insulet Corporation (PODD) : Zacks Investment Research ranks Insulet Corporation (PODD) as 2, which is a Buy recommendation. 8 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. A total of 5 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 14 research analysts is 1.79, which indicates as a Buy.


Also, In a research note released to the investors, Jefferies maintains its rating on Insulet Corporation (NASDAQ:PODD).The analysts at the brokerage house have a current rating of Buy on the shares. In a recent information released to the investors, Jefferies raises the new price target from $41 per share to $45 per share. The rating by the firm was issued on August 4, 2016.

Insulet Corporation (NASDAQ:PODD): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $42.43 and $41.61 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $42.56. The buying momentum continued till the end and the stock did not give up its gains. It closed at $42.46, notching a gain of 0.31% for the day. The total traded volume was 143,564 . The stock had closed at $42.33 on the previous day.

Insulet Corporation is a medical device company engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin infusion system for people with insulin-dependent diabetes. The Companys principal offices are located in Billerica, Massachusetts. Features of the OmniPod System include two-part design, no tubing, and automated cannula insertion. The OmniPod System consists of two devices that communicate wirelessly: the OmniPod, a small, lightweight, disposable insulin infusion device worn beneath clothing; and the PDM, a handheld device much like a personal digital assistant that wirelessly programs the OmniPod with insulin delivery instructions. The OmniPod will operate up to 72 hours (but no more than 80 hours) after it is first activated. The OmniPod System does not have external tubing and features an automated, hands-free cannula insertion system.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.